Background: Recurrent respiratory papillomatosis (RRP) is a wart-like lesion mainly affecting the larynx, caused by human papillomavirus (HPV) genotypes 6 and 11. The disease affects both children and adults, and there is no cure. Surgery is the current symptom-relieving treatment; however, HPV vaccination is used as an adjuvant treatment.
Aims And Objectives: The aims were to study effects of HPV vaccination in RRP cases and to compare juvenile-onset to adult-onset disease and high treatment frequency (TF) to low TF cases.
Material And Methods: Medical records of RRP patients were studied from May 2006 to January 2023. Eighty-five RRP cases, tested for HPV genotypes with PapilloCheck®, were included. Vaccination- onset- and treatment analysis were performed.
Results: Twelve percent of the cases were vaccinated. The number of surgeries decreased from 2.0 to 0.8/year after HPV vaccination. Most cases had an adult-onset and less than one treatment per year. Juvenile-onset cases had a higher vaccination treatment ratio compared to adult-onset.
Conclusions: HPV vaccination was associated with a lower number of treatments per year, supporting the use of vaccination as an adjuvant treatment.
Significance: Vaccination as adjuvant treatment to surgery may lead to increased quality of life for RRP patients and saved healthcare resources.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/00016489.2024.2316264 | DOI Listing |
Ther Adv Vaccines Immunother
January 2025
Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Cervical cancer is the most common cancer in women worldwide. Early screening and vaccination can prevent cervical cancer; however, the low levels of knowledge, attitude, and practice among the young can contribute to the high prevalence of cervical cancer.
Objective: This study aimed to assess the level of knowledge, attitude, and practice of cervical cancer and associated factors among female Health Sciences students of the College of Health Sciences at Addis Ababa University.
Anticancer Agents Med Chem
January 2025
Department of Gynecology, Lanzhou University Second Hospital Lanzhou University, Lanzhou, 730030, China.
Cervical cancer is a significant global health threat, ranking as the fourth most common malignancy among women and resulting in over 300,000 deaths annually. Although screening and vaccination initiatives have led to a decline in incidence rates, treatment options for advanced or recurrent cervical cancer remain inadequate, often proving ineffective and costly. In this context, adenoviral therapy has emerged as a promising strategy to enhance therapeutic outcomes.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department of Thyroid and Breast Surgery, Jining NO. 1 People' Hospital, Jining, China.
This bibliometric and visualization study provides a comprehensive analysis of global research hotspots and trends in DNA vaccine research from 2014 to 2024. By employing data sourced from the Web of Science Core Collection, we identified a total of 3,600 articles. Our analysis reveals a declining trend in annual publications.
View Article and Find Full Text PDFBMC Public Health
January 2025
Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Background: It is estimated that more than 80% of people are infected with human papilloma virus (HPV) at some point in their lives. Knowledge about HPV infection and methods of its prevention is important for society as a whole. Medical students as future healthcare workers must be thoroughly informed about HPV infection in order to properly participate in the promotion of its prevention.
View Article and Find Full Text PDFBackground: Persistent infection with human papillomavirus (HPV) is associated with most cervical and anal cancer cases and a large fraction of other anogenital and oropharyngeal cancers. The prophylactic HPV vaccines are known to prevent HPV infections and HPV-associated disease, although there is evidence of reduced response to the HPV vaccination among individuals living with HIV. Prior studies among individuals without HIV suggest that a single HPV vaccine dose induces humoral immune responses that, while lower than those induced by two or three doses, still confer protection against HPV infection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!